.Charles Baum, M.D., Ph.D., who supervised Mirati Therapies' $ 5.8 billion sale to Bristol Myers Squibb in 2014, is taking the command of young biotech Terremoto Biosciences.Baum's "extensive expertise in medicine development, as well as proven record in advancing high-impact medicines, will be instrumental," outbound chief executive officer Peter Thompson, M.D., pointed out in a July 25 release. Thompson will definitely retain his chair as board chairperson..Baum, a qualified physician-scientist, was actually the creator, president and CEO of oncology-focused Mirati. Just before that, he helped build cancer cells drugs at Pfizer as well as Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Currently, Baum will serve as CEO at Terremoto, a provider building small molecules to target disease-causing proteins-- like those found in cancerous tumor cells-- utilizing covalent bonds. Existing therapies that use covalent connections largely target the amino acid cysteine. However, of the twenty amino acids that compose proteins, cysteine is the least usual. Terremoto is actually rather targeting among the necessary amino acids, amino acid lysine, which is located in almost all proteins.Through targeting amino acid lysine as well as other amino acids, Terremoto wants to alleviate previously undruggable ailments and also develop first-in-class medicines..The biotech, located in South San Francisco, raised $75 thousand in series A backing in 2022. A little greater than a year eventually, the biotech much more than doubled that variety in a $175 thousand set B.